EU revises rules for medicated feed

The proposal on the modernisation of medicated feed legislation now includes feed for pets in its scope and will repeal and substitute the out-dated Directive (90/167/EEC) on the manufacture, placing on the market and use of medicated feed. The proposed rules will ensure that medicated feed can only be manufactured from specifically authorised veterinary medicines and by approved manufacturers.

Antimicrobial resistance (AMR) will be tackled through measures such as a ban on medicated feed being used preventively or as growth promoters. Additionally, EU wide residue limits for veterinary medicines in ordinary feed are established at a limit to avoid the development of AMR. The scope of the proposal explicitly includes medicated feed for pets, so that pets – especially those with chronic diseases, can be treated more easily with innovative medicated pet food.

Rules veterinary medicines simplified

The proposal on veterinary medicinal products aims in particular to make more medicines available in the EU to treat and prevent diseases in animals. With its proposal, the Commission aims to tailor legislation on veterinary medicines to the needs of the veterinary sector whilst continuing to ensure a high level of public and animal health and a safe environment.

The proposed Regulation builds upon existing EU rules for veterinary medicines which ensure that only medicines that have been granted a marketing authorisation can be laced on the market. However, rules are simplified to ensure the development of suitable medicines for animals in the EU. This reduction in red tape will concern both the marketing authorisation procedure and the monitoring of side effects (pharmacovigilance).

The proposed rules are particularly timely for minor species such as bees, goats, turkeys, horses etc. for whom available medicines are currently lacking.To combat AMR and to help keep antibiotics effective in humans and animals, the proposal introduces the possibility of restricting the authorisation and use in animals of certain antimicrobials that are reserved to treat human infections.

Next steps

Other EU institutions, including the European Parliament and the Council, will consider the Commission’s proposals and will adopt their positions in due course, in accordance with the co-decision procedure.